EBUS for Lung Cancer: Our Experience Over 5 Years

<bold>Introduction:</bold> We assessed the diagnostic utility of EBUS procedures from 2018-2022 using the NHS Endobronchial Ultrasound Service Specification standards. In our centre the majority of procedures are performed by a single consultant, however since 2022 a further consultant was involved in a training capacity. <bold>Aims:</bold> To determine if our performance is meeting the expected standards of practice. <bold>Methods:</bold> Patients who underwent an EBUS and had a final diagnosis of lung cancer were included. Data was collected on EBUS diagnosis rates, additional procedures required, samples which were sufficient for immunohistochemistry testing and the number of complications. <bold>Results:</bold> We audited 197 EBUS procedures over the 5 years. A summary of our findings can be seen in table 1. The diagnostic rate has exceeded the target of >90% in all years except for 2020. We have been consistently improving in reaching targets for molecular testing. PDL-1 testing is the only one not to have reached the >90% target, in 2022 this was 89%. In the cohort one patient had bleeding which required adrenaline and another patient’s procedure was prematurely stopped due to discomfort. <bold>Conclusions:</bold> Our service is meeting most of the targets for auditable standards and has shown improvement over the years. We have had very few complications. Further improvement will focus on obtaining enough tissue for PDL-1 testing. <fig><object-id>erj;64/suppl_68/PA1529/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>